{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T12:03:51Z","timestamp":1776513831207,"version":"3.51.2"},"reference-count":83,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Cancer is among the leading causes of death worldwide and it is estimated that in 2040 more than 29 million people will be diagnosed with some type of cancer. The most prevalent type of cancer in women, worldwide, is breast cancer, a type of cancer associated with a huge death rate. This high mortality is mainly a consequence of the development of drug resistance, which is one of the major challenges to overcome in breast cancer treatment. As a result, research has been focused on finding novel therapeutical weapons, specifically ones that allow for a personalized treatment, based on patients\u2019 characteristics. Although the scientific community has been concerned about guaranteeing the quality of life of cancer patients, researchers are also aware of the increasing costs related to cancer treatment, and efforts have been made to find alternatives to the development of new drugs. The development of new drugs presents some disadvantages as it is a multistep process that is time- and money-consuming, involving clinical trials that commonly fail in the initial phases. A strategy to overcome these disadvantages is drug repurposing. In this review, we focused on describing potential repurposed drugs in the therapy of breast cancer, considering their pharmacogenomic profile, to assess the relationship between patients\u2019 genetic variations and their response to a certain therapy. This review supports the need for the development of further fundamental studies in this area, in order to investigate and expand the knowledge of the currently used and novel potential drugs to treat breast cancer. Future clinical trials should focus on developing strategies to group cancer patients according to their clinical and biological similarities and to discover new potential targets, to enable cancer therapy to be more effective and personalized.<\/jats:p>","DOI":"10.3390\/ijms23084280","type":"journal-article","created":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T23:07:16Z","timestamp":1649891236000},"page":"4280","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Drug Repurposing in Cancer Therapy: Influence of Patient\u2019s Genetic Background in Breast Cancer Treatment"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6525-1551","authenticated-orcid":false,"given":"Rafaela","family":"Rodrigues","sequence":"first","affiliation":[{"name":"OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Dr. Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1420-5042","authenticated-orcid":false,"given":"Diana","family":"Duarte","sequence":"additional","affiliation":[{"name":"OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Dr. Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"Faculty of Pharmacy of University of Porto, Rua Jorge Viterbo Ferreira, 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[{"name":"OncoPharma Research Group, Center for Health Technology and Services Research (CINTESIS), Rua Dr. Pl\u00e1cido da Costa, 4200-450 Porto, Portugal"},{"name":"Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Al. Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"},{"name":"Associate Laboratory RISE\u2013Health Research Network, Faculty of Medicine, University of Porto, Al. Prof. Hern\u00e2ni Monteiro, 4200-319 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bukowski, K., Kciuk, M., and Kontek, R. (2020). Mechanisms of Multidrug Resistance in Cancer Chemotherapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21093233"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.2174\/0929867327999200817104912","article-title":"Drug Repurposing in Oncology, an Attractive Opportunity for Novel Combinatorial Regimens","volume":"28","author":"Falvo","year":"2021","journal-title":"Curr. Med. Chem."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ejmech.2018.10.001","article-title":"The use of proteomic technologies to study molecular mechanisms of multidrug resistance in cancer","volume":"162","author":"Cao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.phrs.2017.07.013","article-title":"Drug repurposing in cancer","volume":"124","author":"Sleire","year":"2017","journal-title":"Pharmacol. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/17460441.2021.1883585","article-title":"Artificial intelligence, machine learning, and drug repurposing in cancer","volume":"16","author":"Tanoli","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.semcancer.2019.09.023","article-title":"Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets","volume":"68","author":"Mottini","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"111638","DOI":"10.1016\/j.biopha.2021.111638","article-title":"Drug repurposing: Iron in the fire for older drugs","volume":"141","author":"Sonaye","year":"2021","journal-title":"Biomed Pharm."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.semcancer.2019.12.011","article-title":"Machine and deep learning approaches for cancer drug repurposing","volume":"68","author":"Issa","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1158\/1535-7163.MCT-17-0157","article-title":"Ormeloxifene Suppresses Prostate Tumor Growth and Metastatic Phenotypes via Inhibition of Oncogenic \u03b2-catenin Signaling and EMT Progression","volume":"16","author":"Hafeez","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"bbab048","DOI":"10.1093\/bib\/bbab048","article-title":"DeepDRK: A deep learning framework for drug repurposing through kernel-based multi-omics integration","volume":"22","author":"Wang","year":"2021","journal-title":"Brief Bioinform."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev-pharmtox-010919-023537","article-title":"Using What We Already Have: Uncovering New Drug Repurposing Strategies in Existing Omics Data","volume":"60","author":"Pulley","year":"2020","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/bcp.14964","article-title":"Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target","volume":"88","author":"Islam","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"112275","DOI":"10.1016\/j.ejmech.2020.112275","article-title":"A medicinal chemistry perspective of drug repositioning: Recent advances and challenges in drug discovery","volume":"195","author":"Pillaiyar","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_15","first-page":"2400","article-title":"Editorial: Repurposed Drugs Targeting Cancer Signaling Pathways: Clinical Insights to Improve Oncologic Therapies","volume":"11","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/534314a","article-title":"Can you teach old drugs new tricks?","volume":"534","author":"Nosengo","year":"2016","journal-title":"Nature"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/gm326","article-title":"Drug repositioning for personalized medicine","volume":"4","author":"Li","year":"2012","journal-title":"Genome Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1007\/s00018-019-03134-0","article-title":"Drug repurposing to overcome resistance to various therapies for colorectal cancer","volume":"76","author":"Fong","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.semcancer.2020.03.011","article-title":"Drug rechanneling: A novel paradigm for cancer treatment","volume":"68","author":"Kaushik","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/PPO.0000000000000360","article-title":"Identifying Drug Repurposing Opportunities in Oncology","volume":"25","author":"Orecchioni","year":"2019","journal-title":"Cancer J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","article-title":"Hallmarks of Cancer: New Dimensions","volume":"12","author":"Hanahan","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.2174\/0929867325666180713155702","article-title":"Drug Repurposing in the Development of Anticancer Agents","volume":"26","author":"Olgen","year":"2019","journal-title":"Curr. Med. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e543","DOI":"10.1016\/S1470-2045(20)30610-0","article-title":"Drug repurposing in oncology","volume":"21","author":"Frantzi","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/bmb\/ldaa045","article-title":"Repurposing approved drugs for cancer therapy","volume":"137","author":"Schein","year":"2021","journal-title":"Br. Med. Bull."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"32745","DOI":"10.1038\/srep32745","article-title":"Clustering drug-drug interaction networks with energy model layouts: Community analysis and drug repurposing","volume":"6","author":"Udrescu","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/5584_2021_622","article-title":"Drug Sensitivity and Drug Repurposing Platform for Cancer Precision Medicine","volume":"1326","author":"Nweke","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/978-3-030-24100-1_2","article-title":"Next Generation Sequencing (NGS): A Revolutionary Technology in Pharmacogenomics and Personalized Medicine in Cancer","volume":"1168","author":"Morganti","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ruiz-Garcia, E., and Astudillo-de la Vega, H. (2019). Onco-omics Approaches and Applications in Clinical Trials for Cancer Patients. Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics, Springer. Advances in Experimental Medicine and Biology.","DOI":"10.1007\/978-3-030-24100-1"},{"key":"ref_30","first-page":"111","article-title":"Pharmacogenetics: An Important Part of Drug Development with a Focus on Its Application","volume":"1","author":"Oates","year":"2018","journal-title":"Int. J. Biomed. Investig."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.semcancer.2019.09.012","article-title":"Drug repurposing for breast cancer therapy: Old weapon for new battle","volume":"68","author":"Aggarwal","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"172784","DOI":"10.1016\/j.ejphar.2019.172784","article-title":"Old wine in new bottles: Drug repurposing in oncology","volume":"866","author":"Antoszczak","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.3332\/ecancer.2020.1071","article-title":"Repurposing of drugs for triple negative breast cancer: An overview","volume":"14","author":"Spini","year":"2020","journal-title":"Ecancermedicalscience"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.3727\/096504017X14876245096439","article-title":"Polymorphic Variations Associated With Doxorubicin-Induced Cardiotoxicity in Breast Cancer Patients","volume":"25","author":"Todorova","year":"2017","journal-title":"Oncol Res"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.critrevonc.2017.12.005","article-title":"Protective effects of curcumin against doxorubicin-induced toxicity and resistance: A review","volume":"122","author":"Mohajeri","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Otter, M., Csader, S., Keiser, M., and Oswald, S. (2021). Expression and Functional Contribution of Different Organic Cation Transporters to the Cellular Uptake of Doxorubicin into Human Breast Cancer and Cardiac Tissue. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23010255"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1177\/1535370217746383","article-title":"Immune response proteins as predictive biomarkers of doxorubicin-induced cardiotoxicity in breast cancer patients","volume":"243","author":"Yu","year":"2017","journal-title":"Exp. Biol. Med."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Denard, B., Jiang, S., Peng, Y., and Ye, J. (2018). CREB3L1 as a potential biomarker predicting response of triple negative breast cancer to doxorubicin-based chemotherapy. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4724-8"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Denard, B., Pavia-Jimenez, A., Chen, W., Williams, N.S., Naina, H., Collins, R., Brugarolas, J., and Ye, J. (2015). Identification of CREB3L1 as a Biomarker Predicting Doxorubicin Treatment Outcome. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0129233"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200544110-00003","article-title":"Clinical pharmacokinetics of cyclophosphamide","volume":"44","author":"Huitema","year":"2005","journal-title":"Clin. Pharmacokinet"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1111\/bcp.14031","article-title":"The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomes","volume":"85","author":"Helsby","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Hlav\u00e1\u010d, V., Hol\u00fd, P., and Sou\u010dek, P. (2020). Pharmacogenomics to Predict Tumor Therapy Response: A Focus on ATP-Binding Cassette Transporters and Cytochromes P450. J. Pers. Med., 10.","DOI":"10.3390\/jpm10030108"},{"key":"ref_43","first-page":"73","article-title":"Everolimus in the Treatment of Metastatic Breast Cancer","volume":"9","author":"Royce","year":"2015","journal-title":"Breast Cancer"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1109653","article-title":"Everolimus in Postmenopausal Hormone-Receptor\u2013Positive Advanced Breast Cancer","volume":"366","author":"Baselga","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nrc2683","article-title":"CYP2D6 and tamoxifen: DNA matters in breast cancer","volume":"9","author":"Hoskins","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Pascual, T., Apell\u00e1niz-Ruiz, M., Pernaut, C., Cueto-Felgueroso, C., Villalba, P., \u00c1lvarez, C., Manso, L., Inglada-P\u00e9rez, L., Robledo, M., and Rodr\u00edguez-Antona, C. (2017). Polymorphisms associated with everolimus pharmacokinetics, toxicity and survival in metastatic breast cancer. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0180192"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1055\/s-0038-1676303","article-title":"Impacts of Cytochrome P450 2D6 (CYP2D6) Genetic Polymorphism in Tamoxifen Therapy for Breast Cancer","volume":"40","author":"Bezerra","year":"2018","journal-title":"Rev. Bras. Ginecol. Obstet."},{"key":"ref_48","first-page":"111","article-title":"CYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: A preliminary retrospective study","volume":"9","author":"Wickramage","year":"2017","journal-title":"Breast Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10549-017-4400-8","article-title":"CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: Results from a population-based study","volume":"166","author":"Hertz","year":"2017","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s10549-004-7751-x","article-title":"Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients","volume":"91","author":"Nowell","year":"2005","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"R284-90","DOI":"10.1186\/bcr993","article-title":"Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients","volume":"7","author":"Wegman","year":"2005","journal-title":"Breast Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-19-3091","article-title":"Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor \u03b1","volume":"26","author":"Ingle","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e137571","DOI":"10.1172\/jci.insight.137571","article-title":"Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action","volume":"5","author":"Cairns","year":"2020","journal-title":"JCI Insight"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"106454","DOI":"10.18632\/oncotarget.22461","article-title":"Pharmacogenetics of response to neoadjuvant paclitaxel treatment for locally advanced breast cancer","volume":"8","author":"Ramirez","year":"2017","journal-title":"Oncotarget"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Eng, L., Ibrahim-Zada, I., Jarjanazi, H., Savas, S., Meschian, M., Pritchard, K.I., and Ozcelik, H. (2011). Bioinformatic analyses identifies novel protein-coding pharmacogenomic markers associated with paclitaxel sensitivity in NCI60 cancer cell lines. BMC Med. Genom., 4.","DOI":"10.1186\/1755-8794-4-18"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.clbc.2021.02.005","article-title":"Aspirin Use and Risk of Breast Cancer: A Meta-analysis of Observational Studies from 1989 to 2019","volume":"21","author":"Ma","year":"2021","journal-title":"Clin. Breast Cancer"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.clbc.2019.05.004","article-title":"Aspirin Treatment Effect and Association with PIK3CA Mutation in Breast Cancer: A Biomarker Analysis","volume":"19","author":"Zhou","year":"2019","journal-title":"Clin. Breast Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1158\/0008-5472.CAN-16-2400","article-title":"Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling","volume":"77","author":"Henry","year":"2017","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"112375","DOI":"10.1016\/j.biopha.2021.112375","article-title":"Drugs repurposed: An advanced step towards the treatment of breast cancer and associated challenges","volume":"145","author":"Malik","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"102019","DOI":"10.1016\/j.ctrv.2020.102019","article-title":"Review of precision cancer medicine: Evolution of the treatment paradigm","volume":"86","author":"Tsimberidou","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41392-020-0110-5","article-title":"Targeting cancer stem cell pathways for cancer therapy","volume":"5","author":"Yang","year":"2020","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2174\/157489281602210806102833","article-title":"Current Status and Future Perspectives on Old Drug Repurposing for Cancer Treatment","volume":"16","author":"Dou","year":"2021","journal-title":"Recent Patents Anti-Cancer Drug Discov."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1016\/j.cell.2017.11.009","article-title":"Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy","volume":"171","author":"Palmer","year":"2017","journal-title":"Cell"},{"key":"ref_64","first-page":"871","article-title":"Effects of Combinations of Antileukemic Agents on an Acute Lymphocytic Leukemia of Mice*","volume":"12","author":"Law","year":"1952","journal-title":"Cancer Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood.V26.5.642.642","article-title":"The effectiveness of combinations of antileukemic agents in inducing and maintaining remission in children with acute leukemia","volume":"26","author":"Frei","year":"1965","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1182\/blood.V18.4.431.431","article-title":"Studies of Sequential and Combination Antimetabolite Therapy in Acute Leukemia: 6-Mercaptopurine and Methotrexate","volume":"18","author":"Frei","year":"1961","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Acute Leukemia Group B, Freireich, E.J., Gehan, E., Frei, E., Schroeder, L.R., Wolman, I.J., Anbari, R., Burgert, E.O., Mills, S.D., and Pinkel, D. (1963). The Effect of 6-Mercaptopurine on the Duration of Steroid-induced Remissions in Acute Leukemia: A Model for Evaluation of Other Potentially Useful Therapy. Blood, 21, 699\u2013716.","DOI":"10.1182\/blood.V21.6.699.699"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrd.2016.3","article-title":"Combination therapies in oncology","volume":"15","author":"Webster","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.bbrc.2005.04.143","article-title":"Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways","volume":"332","author":"Hwang","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/s41598-020-58438-0","article-title":"Identification of synergistic drug combinations using breast cancer patient-derived xenografts","volume":"10","author":"Turner","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s11060-019-03360-3","article-title":"Rapamycin and hydroxychloroquine combination alters macrophage polarization and sensitizes glioblastoma to immune checkpoint inhibitors","volume":"146","author":"Hsu","year":"2020","journal-title":"J. Neurooncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.addr.2015.10.022","article-title":"Recent advances of cocktail chemotherapy by combination drug delivery systems","volume":"98","author":"Hu","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/jnci\/djy149","article-title":"Auranofin\/Vitamin C: A Novel Drug Combination Targeting Triple-Negative Breast Cancer","volume":"111","author":"Hatem","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"448","DOI":"10.14348\/molcells.2019.2395","article-title":"Combination Therapy with a PI3K\/mTOR Dual Inhibitor and Chloroquine Enhances Synergistic Apoptotic Cell Death in Epstein-Barr Virus-Infected Gastric Cancer Cells","volume":"42","author":"Kim","year":"2019","journal-title":"Mol. Cells"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e12402","DOI":"10.1111\/cpr.12402","article-title":"Fluoxetine induces autophagic cell death via eEF2K-AMPK-mTOR-ULK complex axis in triple negative breast cancer","volume":"51","author":"Sun","year":"2018","journal-title":"Cell Prolif."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.3892\/mmr.2015.3967","article-title":"Dopamine receptor antagonist thioridazine inhibits tumor growth in a murine breast cancer model","volume":"12","author":"Yin","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s13277-012-0377-4","article-title":"Fluoxetine synergys with anticancer drugs to overcome multidrug resistance in breast cancer cells","volume":"33","author":"Zhou","year":"2012","journal-title":"Tumour. Biol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"El-Gowily, A.H., Loutfy, S.A., Ali, E.M.M., Mohamed, T.M., and Mansour, M.A. (2021). Tioconazole and Chloroquine Act Synergistically to Combat Doxorubicin-Induced Toxicity via Inactivation of PI3K\/AKT\/mTOR Signaling Mediated ROS-Dependent Apoptosis and Autophagic Flux Inhibition in MCF-7 Breast Cancer Cells. Pharmaceuticals, 14.","DOI":"10.3390\/ph14030254"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"299","DOI":"10.5306\/wjco.v6.i6.299","article-title":"Fluoxetine induces cytotoxic endoplasmic reticulum stress and autophagy in triple negative breast cancer","volume":"6","author":"Bowie","year":"2015","journal-title":"World J. Clin. Oncol"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Kumari, K., Keshari, S., Sengupta, D., Sabat, S.C., and Mishra, S.K. (2017). Transcriptome analysis of genes associated with breast cancer cell motility in response to Artemisinin treatment. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3863-7"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Duarte, D., and Vale, N. (2020). New Trends for Antimalarial Drugs: Synergism between Antineoplastics and Antimalarials on Breast Cancer Cells. Biomolecules, 10.","DOI":"10.3390\/biom10121623"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Duarte, D., Cardoso, A., and Vale, N. (2021). Synergistic Growth Inhibition of HT-29 Colon and MCF-7 Breast Cancer Cells with Simultaneous and Sequential Combinations of Antineoplastics and CNS Drugs. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147408"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Duarte, D., R\u00eama, A., Amorim, I., and Vale, N. (2022). Drug Combinations: A New Strategy to Extend Drug Repurposing and Epithelial-Mesenchymal Transition in Breast and Colon Cancer Cells. Biomolecules, 12.","DOI":"10.3390\/biom12020190"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/8\/4280\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:53:41Z","timestamp":1760136821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/8\/4280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":83,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,4]]}},"alternative-id":["ijms23084280"],"URL":"https:\/\/doi.org\/10.3390\/ijms23084280","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,14]]}}}